blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3288580

EP3288580 - GLYCAN-DEPENDENT IMMUNOTHERAPEUTIC MOLECULES [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  04.11.2022
Database last updated on 03.09.2024
FormerExamination is in progress
Status updated on  25.10.2019
FormerRequest for examination was made
Status updated on  02.02.2018
FormerThe international publication has been made
Status updated on  11.11.2016
Most recent event   Tooltip04.11.2022Refusal of applicationpublished on 07.12.2022  [2022/49]
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[2018/10]
Inventor(s)01 / DEMETRIOU, Michael
2 Twain Street
Irvine, CA 92317 / US
02 / ZHOU, Raymond, Wenhou
6981 23rd Street
Sacramento, CA 95822 / US
 [2018/10]
Representative(s)Leonard, Thomas Charles, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2018/10]
Application number, filing date16789833.729.04.2016
[2018/10]
WO2016US30113
Priority number, dateUS201562155761P01.05.2015         Original published format: US 201562155761 P
[2018/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016178996
Date:10.11.2016
Language:EN
[2016/45]
Type: A1 Application with search report 
No.:EP3288580
Date:07.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 10.11.2016 takes the place of the publication of the European patent application.
[2018/10]
Search report(s)International search report - published on:KR10.11.2016
(Supplementary) European search report - dispatched on:EP26.11.2018
ClassificationIPC:A61K38/17, A61K39/395, C07K14/00, A61K38/16, A61K48/00, A61P35/00
[2020/27]
CPC:
A61K38/168 (EP,KR,US); A61K38/1732 (KR,RU); A61K47/6849 (US);
A61K38/178 (EP); A61K48/00 (KR); A61P35/00 (EP,KR,RU,US);
C07K14/4726 (EP); C07K16/2809 (EP,US); C07K16/2851 (US);
C07K2317/24 (US); C07K2317/31 (US); C07K2317/622 (EP,US);
C07K2319/02 (EP); C07K2319/21 (EP); C07K2319/33 (EP,US) (-)
Former IPC [2018/10]A61K38/17, A61K38/16, A61K48/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/10]
TitleGerman:GLYCAN-ABHÄNGIGE IMMUNTHERAPEUTISCHE MOLEKÜLE[2018/10]
English:GLYCAN-DEPENDENT IMMUNOTHERAPEUTIC MOLECULES[2018/10]
French:MOLÉCULES IMMUNOTHÉRAPEUTIQUES DÉPENDANT DE GLYCANE[2018/10]
Entry into regional phase30.11.2017National basic fee paid 
30.11.2017Search fee paid 
30.11.2017Designation fee(s) paid 
30.11.2017Examination fee paid 
Examination procedure30.11.2017Examination requested  [2018/10]
30.11.2017Date on which the examining division has become responsible
21.06.2019Amendment by applicant (claims and/or description)
30.10.2019Despatch of a communication from the examining division (Time limit: M04)
09.03.2020Reply to a communication from the examining division
16.10.2020Despatch of a communication from the examining division (Time limit: M04)
26.02.2021Reply to a communication from the examining division
23.06.2022Cancellation of oral proceeding that was planned for 27.06.2022
27.06.2022Date of oral proceedings (cancelled)
25.07.2022Despatch of communication that the application is refused, reason: substantive examination [2022/49]
04.08.2022Application refused, date of legal effect [2022/49]
Divisional application(s)EP22182364.4  / EP4088732
Fees paidRenewal fee
27.04.2018Renewal fee patent year 03
29.04.2019Renewal fee patent year 04
27.04.2020Renewal fee patent year 05
27.04.2021Renewal fee patent year 06
27.04.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]IL198479  (PROCOGNIA ISRAEL LTD [IL], et al) [X] 12,13 * page 11 * * claims 1-26 * [Y] 1-5,7-9,11,14,15;
 [XYI]WO2013151649  (SIALIX INC [US]) [X] 12,13 * paragraphs [0100] , [0189] - [0190] - [0196] , [0197] * * claims 1-47 * [Y] 1-5,7-9,11,14,15 [I] 1-5,7-9,11,14,15;
 [XI]WO2015054600  (SIAMAB THERAPEUTICS INC [US]) [X] 12,13 * paragraphs [0209] , [0242] , [0248] - [0272] * * claims 29-30 * [I] 1-5,7-9,11,14,15;
 [XPI]WO2016057916  (SIAMAB THERAPEUTICS INC [US]) [XP] 12,13 * paragraphs [0024] - [0027] - [0177] - [0186] - [0205] - [0228] - [0318] - [0348] * [I] 1-5,7-9,11,14,15;
 [E]WO2016077526  (SIAMAB THERAPEUTICS INC [US]) [E] 1-15 * claims 1-75 *;
 [AP]  - DANYANG FENG ET AL, "Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines", ACS CHEMICAL BIOLOGY, (20160101), vol. 11, no. 4, doi:10.1021/acschembio.6b00084, ISSN 1554-8929, pages 850 - 863, XP055428997 [AP] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1021/acschembio.6b00084
International search[A]US2006148681  (LEI HUAN-YAO [TW], et al) [A] 1-48 * See the whole document. *;
 [A]US2010104572  (LURIA SYLVIE [IL]) [A] 1-48 * See abstract; claims 41-51; and paragraphs [0116]-[0154]. *;
 [A]WO2011145085  (PROCOGNIA ISRAEL LTD [IL], et al) [A] 1-48 * See the whole document. *;
 [A]WO2015017734  (UNIV ARKANSAS [US]) [A] 1-48* See the whole document. *;
 [XA]  - MEDEIROS et al., "A Tn antigen binding lectin from Myrsine coriacea displays toxicity in human cancer cell lines", Journal of Natural Medicines, (20130000), vol. 67, no. 2, pages 247 - 254, XP055328615 [X] 1-9, 19-27, 39-44, 46 * See abstract; pages 250-251; and Table 4. * [A] 10-18, 28-38, 45, 47-48

DOI:   http://dx.doi.org/10.1007/s11418-012-0671-x
by applicantUS4708871
 US5350674
 US5399346
 US5580859
 US5585362
 US5589466
 US5858358
 US5883223
 US5993434
 US6103489
 US6181964
 WO0129058
 US6233482
 US6241701
 US6326193
 WO0196584
 US6352694
 US6516223
 US6534055
 US6567694
 US6678556
 US2004014645
 US6692964
 US2004059285
 US2004092907
 US2004101519
 US6797514
 US2005052630
 US6867041
 US2005070841
 US6887466
 US6905680
 US6905681
 US6905874
 US2006034810
 US2006121005
 US7067318
 US7144575
 US7171264
 US7173116
 US7172869
 US7175843
 US2007128708
 US7232566
 US2013287748
 US2014099309
 US2014271635
 US2014370017
    - STAERZ et al., Nature, (19850000), vol. 314, pages 628 - 631
    - SCOTT et al., Nat Rev Cancer, (20120000), vol. 12, pages 278 - 287
    - HAANEN et al., J. Exp. Med., (19990000), vol. 190, no. 9, page 13191328
    - HOUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
    - ROBERGE J Y et al., Science, (19950000), vol. 269, pages 202 - 204
    - ALTSCHUL, S. et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - REEDIJK et al., The EMBO Journal, (19920000), vol. 11, no. 4, page 1365
    - ULYSSE, L. et al., J. Am. Chem. Soc., (19950000), vol. 117, pages 8466 - 8467
    - G. BARANYR. B. MERRIFIELD, The Peptides: Analysis Synthesis, Biology, Academic Press, (19800000), vol. 2, pages 3 - 254
    - CHRISTIAN et al., J. Mol. Biol., (19920000), vol. 227, page 711
    - DEVLIN et al., Science, (19900000), vol. 249, page 404
    - CWIRLA et al., Proc. Natl. Acad, Sci. USA, (19900000), vol. 87, page 6378
    - LIMBACH et al., Nucleic Acids Res., (19940000), vol. 22, pages 2183 - 2196
    - UI-TEI et al., FEBS Letters, (20000000), vol. 479, pages 79 - 82
    - GHOSH et al., Glycobiology, (19910000), vol. 5, pages 505 - 10
    - SCHENBORNMIERENDORF, Nuc Acids Res., (19850000), vol. 13, pages 6223 - 36
    - NACHEVABERZAL-HERRANZ, Eur. J. Biochem., (20030000), vol. 270, pages 1485 - 65
    - COUGOT et al., Trends in Biochem. Sci., (20010000), vol. 29, pages 436 - 444
    - STEPINSKI et al., RNA, (20010000), vol. 7, pages 1468 - 95
    - ELANGO et al., Biochim. Biophys. Res. Commun., (20050000), vol. 330, pages 958 - 966
    - NISHIKAWA et al., Hum Gene Ther., (20010000), vol. 12, no. 8, pages 861 - 70
    - LIU et al., Cell, (19910000), vol. 66, pages 807 - 815
    - HENDERSON et al., Immun., (19910000), vol. 73, pages 316 - 321
    - BIERER et al., Curr. Opin. Immun., (19930000), vol. 5, pages 763 - 773
    - BERG et al., Transplant Proc., (19980000), vol. 30, no. 8, pages 3975 - 3977
    - GARLAND et al., J. Immunol Meth., (19990000), vol. 227, no. 1-2, pages 53 - 63
    - ERTL et al., Cancer Res, (20110000), vol. 71, pages 3175 - 81
    - JUNGHANS, Journal of Translational Medicine, (20100000), vol. 8, page 55
    - KIMVARKI, Glycoconj J, (19970000), vol. 14, pages 569 - 576
    - HAKOMORI, PNAS USA, (20020000), vol. 99, pages 10231 - 10233
    - KANEDA et al., J Biol Chem, (20020000), vol. 277, pages 16928 - 16935
    - BARRETT et al., Ann Rev Med, (20140000), vol. 65, pages 333 - 347
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.